Hepatic Steatosis Index and Predicted Cardiovascular Risk in a Population-Based Study
- VernacularTitle:Элэг өөхлөлтийн индекс ба зүрх судасны өвчний эрсдлийн түвшин хоорондын хамаарлыг судлах нь
- Author:
Narangerel B
1
;
Batzorig B
2
;
Bayarbold D
2
;
3
;
Khangai E
4
;
OyunSuren E
3
;
Enkhtur Ya
5
;
Oyuntugs B
6
;
Byambajav Ts
1
Author Information
1. Department of Gastroenterology, School of Medicine, MNUMS
2. Department of Epidemiology and Biostatistics, School of Public Health, MNUMS
3. Ministry of Health
4. Department of Family Medicine, School of Medicine, MNUMS
5. School of Medicine, MNUMS
6. Department of Endocrinology, School of Medicine, MNUMS
- Publication Type:Journal Article
- Keywords:
Metabolic dysfunction–associated steatotic liver disease;
insulin resistance;
dyslipidemia
- From:
Mongolian Journal of Health Sciences
2026;93(3):64-69
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of chronic liver disease and is increasingly linked to cardiovascular disease (CVD), the leading cause of mortality globally.
Aim:To evaluate individuals participating in early screening using the Hepatic Steatosis Index (HSI) and examine its association with CVD risk levels.
Materials and Methods:This population-based retrospective cross-sectional study included 47,542 adults aged 40–70 years who participated in a national screening program between 2023 and 2025. Hepatic steatosis was assessed using the Hepatic Steatosis Index (HSI) and categorized as <30 (no steatosis), 30–36 (indeterminate), and >36 (steatosis). Ten-year CVD risk was estimated using laboratory-based WHO cardiovascular disease risk charts for Central Asia. Associations were evaluated using logistic regression and expressed as odds ratios (ORs) with 95% confidence intervals (CIs).
Result:The mean age of participants was 53.18±8.17 years, and 67.1% (31,886) were women. The prevalence of HSI <30, 30–36, and >36 was 8.9% (4,219), 32.1% (15,271), and 59.0% (28,052), respectively. The distribution of low-, moderate-, and high-risk CVD groups was 48.6% (23,115), 41.3% (19,637), and 10.1% (4,790), respectively. The proportion of individuals with high CVD risk was 5.5% in the HSI <30 group and 10.1% in the HSI >36 group. Compared with the reference group, the odds of high CVD risk were increased in the HSI 30–36 group (OR=1.333; 95% CI: 1.152–1.542) and the HSI >36 group (OR=2.401; 95% CI: 2.094–2.753). These associations remained statistically significant after adjustment for age, sex, systolic blood pressure, waist circumference, physical inactivity, and smoking.
Conclusion:The prevalence of hepatic steatosis in the study population was 59.0%. Individuals with hepatic steatosis had a 1.2-fold higher risk of cardiovascular disease compared with those without steatosis.
- Full text:202609270139231552508_64-69_Элэг өөхлөлтийн индекс ба зүрх судасны өвчний эрсдлийн түвшин хоорондын хамаарлыг судлах нь.pdf
